LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia
Trial Timeline
Dec 1, 2012 → Jan 1, 2015
NCT ID
NCT01709500About LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo is a phase 3 stage product being developed by Sanofi for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01709500. Target conditions include Heterozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01709500 | Phase 3 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Evolocumab + Placebo | Amgen | Phase 3 | 76 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 76 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 32 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 76 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 76 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 76 |
| Praluent | Sanofi | Approved | 84 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 51 |
| lerodalcibep | Medpace | Phase 3 | 74 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |